source
- Sanofi asks FDA to withdraw teplizumab from fast-track review after internal disagreementSanofi has formally requested that the U.S. Food and Drug Administration remove its type 1 diabetes therapy, teplizumab, from the agency's new speedy review program. The request follows a disagree…
- Roche to acquire digital pathology firm PathAI in deal potentially worth over $1BRoche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.